PCSA Processa Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1533743 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,393.5%
TTM EPS YoY34.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-203.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets1.0%
Debt / equity—
Current ratio97.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.07x
Accruals ratio-189.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | $0 | $0 |
| R&D expense | $7.81M | $7.27M | $5.80M | $11.49M | $6.88M |
| SG&A expense | $6.18M | $4.78M | $5.66M | $8.76M | $4.69M |
| Operating income | -$13.99M | -$12.05M | -$11.46M | -$27.53M | -$12.13M |
| Interest expense | — | — | — | — | $362 |
| Pretax income | -$13.56M | -$11.85M | -$11.12M | -$27.42M | -$11.96M |
| Income tax | — | — | — | — | -$530,611 |
| Net income | -$13.56M | -$11.85M | -$11.12M | -$27.42M | -$11.43M |
| EBITDA | -$13.99M | -$12.05M | -$11.46M | — | -$12.13M |
| EPS (basic) | -10.36 | -96.78 | -8.48 | -34.05 | -0.75 |
| EPS (diluted) | -10.36 | -96.78 | -8.48 | -34.05 | -0.75 |
| Weighted avg. shares (diluted) | 1.31M | 122,438 | 1.31M | 805,477 | 15.32M |
| Balance sheet | |||||
| Cash & equivalents | $5.54M | $1.19M | $4.71M | $6.50M | $16.50M |
| Current assets | $5.67M | $1.88M | $5.63M | $8.39M | $18.33M |
| PP&E, net | $4,000 | $5,016 | $2,554 | — | — |
| Intangibles | — | — | — | — | $8.06M |
| Total assets | $7.81M | $3.23M | $5.79M | $8.62M | $26.46M |
| Current liabilities | $2.24M | $1.53M | $730,579 | $998,556 | $971,020 |
| Total liabilities | $2.24M | $1.53M | $797,484 | $1.15M | $978,405 |
| Shareholders' equity | $5.58M | $1.70M | $4.99M | $7.47M | $25.49M |
| Shares outstanding | 2.57M | 148,108 | 1.29M | 801,774 | 15.71M |
| Cash flow statement | |||||
| Operating cash flow | -$11.39M | -$11.25M | -$8.06M | -$9.61M | -$8.72M |
| Capital expenditure | — | $3,244 | $2,776 | — | — |
| Free cash flow | — | -$11.25M | -$8.07M | — | — |
| Investing cash flow | -$850,000 | -$3,244 | -$2,776 | — | — |
| Financing cash flow | $16.58M | $7.73M | $6.27M | -$388,843 | $9.80M |
| Depreciation & amortization | $1,204 | $782 | $222 | — | $484 |
| Stock-based compensation | $857,550 | $629,514 | $1.06M | $8.83M | $3.41M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.